Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A key part of Amgen’s strategy was to broaden the indications for those drugs it already owned, with Epogen successfully obtaining indications for anaemia in cancer patients, Enbrel broadening ...

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.” ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer ...

In my opinion, thanks in part to Blincyto, Enbrel, Imdelltra, Tezspire, and Amjevita/Amgevita, Amgen is getting closer to the leaders in these markets, namely AstraZeneca (AZN) and Johnson ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Key Drugs Driving AMGN’s Top Line Amgen is seeing declining revenues from oncology biosimilars and some legacy established products like Enbrel. Pricing headwinds and competitive pressure are ...